DOCSLIB.ORG

Author Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index INDEX TO PROCEEDINGS SUPPLEMENTS TO VOLUMES 81, 82 and 83 AUTHOR INDEX ABBCT, W.M. & STRANGE, P.G. Use of ANIS, N.A., BERRY, S.C., BURTON, N.R., immobilised lectins for partial DAWKINS, S.L. & LODGE, D. Effects purification of D2 dopamine receptors, of psychotomimetic benzomorphans on 113P responses of cat spinal neurones to ABRAHAMSEN, J. & NE ERGAARD, O.A. excitatory amino acids and acetyl- Accumulation of [ H]-adrenaline by choline, 196P rabbit isolated aorta, 327P ANWYL, R. & ROWAN, M.J. Antagonism ADAMS, M. & MARSHALL, I. Chronic of inhibitory but not excitatory infusions of idazoxan and desmeth- effects of 5-hydroxytryptamine in the ylimipramine on cr2-receptor control rat hippocampal slice, 273P of noradrenaline release, 316P APPLEYARD, M.E., GREEN, A.R. & SMITH, ADHAM, N. & TEMPLETON, D. The effect A.D. Regional acetylcholinesterase of parasympathetic denervation on activity in rat brain following a [ H]-QNB binding in the rat parotid convulsion, 248P gland, 323P ARBILLA, S., BAUD, P., CANTRILL, R. & AL-GADI, M. & HILL, S.J. The effect LANGER, S.Z. Endogenous phenolamines: of cimetidine and mepyramine on do they have a direct postsynaptic histamine stimulated cAMP accumulation action on dopamine receptors in the in rabbit cerebral cortical slices, central nervous system? 252P 278P ARBILLA, S., DENNIS, T., LANGER, S.Z., ALABASTER, V.A. & PETERS, C.J. Pre- NIDDAM, R. & SCATTON, B. Pretreatment and post-junctional 62-adrenoceptors with reperpine does not modify the can be differentially antagonised, amphetamine induced release of 163P endogenous dopamine in striatal ALDERSON, E. see MARSHALL, E.F., 351P slices, 249P ALLELY, M. & UNGAR, A. The effect ARCHER, D.R. & LYLES, G.A. Amine of thyroid state on the responses oxidase activities in dissociated of conscious dogs to propranolol, cell fractions from rat skeletal sotalol and nadolol, 7P muscle, 421P ALPS, B.J., BROWN, C.M., CALDER, C. ARENSON, M.S. & NISTRI, A. Intracellul- & KILPATRICK, A.T. Brain dopamine ar studies of the action of K+ channel levels following experimental cerebral blockers on frog motoneuronal respons- ischaemia, 449P es to excitatory amino acids, 152P ANDERSON, D.R., CABEROS, L., FENN, C.G. ARMSTRONG, R.A., JONES, R.L., & LITTLETON, J.M. Reduced platelet PEESAPATI, V., WILL, S.G. & WILSON function in rats treated chronically N.H. Efect of the thromboxane recept- with ethanol, 322P or antagonist EP 092 on the early ANDERSON, R.A. & MITCHELL, R. Benzo- phase of endotoxin shock in the sheep, diazepines potentiate the effect of 72P muscimol on prolactin secretion ARR, S.M., COOPER,W.D., CRUTCHER, E.C. in vitro, 343P & QUINN, P.J. The effects of pro- ANDERSON, S., LLEWELLYN, K.D., SNOOK, G. pranolol and timolol on rat heart & WILSON, J.F. Penetration of 6d- mitochondrial function, 223P melanocyte-stimulating hormone through ARUNDEL, P.A., BILSKI, A.J.T. & THOMSON the blood-brain barrier in the rat, D.S. A new photometric method for 106P quantifying erythema induced by UV- ANGELL, D., CLOUGH, D.P., HATTON, R. B irradiation, 192P & ROBERTS, A.J. The effect of ATTERWILL, C.K. Effect of thyroid enalapril and bilateral nephrectomy status on the different forms of on sympathetic function in normo- Na , K -ATPase in immature and mature tensive rats, 339P rat brain, 450P ANGELO-KHATTAR, M., JOSEPH, L., NILSSON, T. & THULESIUS, 0. The effect of indomethacin on ureteral motility, 230P ATTERWILL, C.K. & NUTT, D.J. Thyroid 5-HT uptake in rat brain by molecules hormones do not alter rat brain benzo- possessing long alkyl side chains, diazepine receptor function in vivo, 425P 194P BARBER, D.J., BARBOUR-McMULLEN, J. & ATTERWILL, C.K., NICHOLLS, J. & PRINCE, COOPER, S.J. Opiate receptor A.K. Cholinergic function in develop- antagonists attenuate sweetened milk ing rat brain cell cultures: effects consumption in male and female rats of thyroid hormone, 32P of the Roman strains, 291P AZAMI, J., FOZARD, J.R., ROUND, A.A. BARBER, H.E., PETRIE, J.C. & SMITH, K.J. & WALLIS, D.I. Selective blockade by A comparison of cimetidine and MDL 72222 of the depolarizing action ranitidine: effect on liver blood of 5-hydroxytryptamine on vagal flow, 93P primary afferents, 129P BARBOUR-McMULLEN, J. see BARBER, D.J., 291P BACK, D.J. & RIVIERE, J.H. Inhibition BARNETT, D.B., COOK, N. & NAHORSKI, of drug metabolism by mefloquine, S.R. Characterisation of the binding 433P of 125 l-(-)pindolol to human platelet BACK,D.J., SUTCLIFFE, F. & TJIA, J.F. -adrenoceptors, 160P Tolbutamide is a good model drug for BARNETT, D.B., NAHORSKI, S.R. & 3 the study of enzyme induction and RICHARDSON, A. Modulation of [ H]- enzyme inhibition in the rat, 149P dihydroergocryptine and [ H]-yohimbine BAILEY, S.J. & JORDAN, C.C. Loss of binding sites on human platelets activity of tachykinins in smooth during the menstrual cycle, 159P muscle: relevance to potency estimates BARR, J, & SKETT, P. The role of in vitro, 61P cytochrome P-450, NADPH-cytochrome BAKER, S., FLOCKHART, I.R., MARSHALL, P-450 reductase and lipids in sex I., TULLOCH, I.F. & WALTER, D.S. differences in hepatic drug metabol- Locus coeruleus lesions abolish feed- ism, 396P back of noradrenaline onto 'presynap- BARR, R.M., FRANCIS, D.M., GREAVES, M.W. tic' - 2-adrenoceptors in rat cerebral & KOZUKA, T. Prostaglandin D 2 release cortex, 49P by guinea-pig skin during in vitro BALFOUR, D.J.K. & COPLAND, A.M. anaphylaxis, 99P Effects of diazepam on the concent- BARRETT, K.E., PEARCE, F.L. & THOMPSON, ration and biosynthesis of 5- hydrox- H. Histamine secretion from mast ytryptamine in rat brain, 354P cells stimulated with nerve growth BALFOUR, D.J.K. & IYANIWURA, T.T. factor, 90P Studies on the effects of d-ampheta- BATES, R.F.L., BUCKLEY, G.A. & MCARDLE, mine on brain 5-HT and plasma cortico- C.A. Comparison of the antiociceptive sterone in stressed rats, 457P effects of centrally administered - - - The effects of d- amphetamine calcitonins and calcitonin gene- on brain 5-hydroxytryptamine and related peptide, 295P plasma corticosterone in unstressed - - - Pressor effect of centrally rats, 456P administered salmon calcitonin (sCT), BALFOUR, D.J.K., BATTIG, K., FITZGERALD, 408P R. & OETTINGER, R. The effects of BATES, R.F.L., BUCKLEY, G.A., EGLEN, nicotine on the behaviour of two R.M. & MCARDLE, C.A. Possible strains of rats in a combined maze- mechanisms of action of calcitonin in open field, 376P haemorrhagic hypotension, 157P, BALFOUR, D.J.K., LAMBERT, J.J., LYLES, BATTIG, K. see BALFOUR, D.J.K., 376P G.A., OGG, G.D. & STEVENSON, I.H. BAUD, P. see ARBILLA, S., 252P Basic self-assessment tutorials in BEATTIE, D.E., MORONEY, M-A. & WYLLIE, pharmacology, 463P M.G. Interrelationship between Na BALL, H.A. & PARRATT, J.R. Effects K -ATPase and K -ATPase in gastric of a new thromboxane receptor antag- mucosa, 398P onist, AH23848, on the acute cardio- BENKELFAT, C., GALZIN, A.M., LANGER, pulmonary responses to E. Coli endo- S.Z., LOO, H., POIRIER, M.F., toxin in cats, 379P SCHOEMAKER, H., SECHTER, D., SEGONZAC, BANSAL, S.J., BRECKENRIDGE, R.J., A. & ZARIFIAN, E. [ H]-imipramine IVERSEN, L.L., SUCKLING, C.J., binding in human blood platelets: WATLING, K.J. & WILLIAMS, L.C. changes after chronic chlorimipramine Non-selective inhibition of GABA and treatment, 352P BENNETT, G.W., LIGHTON, C. & MARSDEN BERRY, S.C. see ANIS, N.A., 196P C.A. The effects of 5,7-dihidroxy- BEY, P., FOZARD,J., MCDONALD, I., tryptamine and p-chlorophenylaline PALFREYMAN, M.G. & ZREIKA, M. MDL on the ex vivo release of thyro- 72145: a potent and selective trophin releasing hormone, 267P inhibitor of MAO type B, 50P BENNETT, P.N., NOTARIANNI, L.J. & PATEL, BILL, D.J. & STEPHENS, R.J. Clonidine D.K. Capacity limited metabolism of reverses reserpine-induced hypothermia acetylsalicyclic acid in the rat, in the mouse via activation of central 228P post-synaptic .12-adrenoceptors? 372P BENNETT, P.N., NOTARIANNI, L.J. & BILSKI, A.J.T. see ARUNDEL, P.A., 192P WORLOCK, A.J. Metabolism of ligno- BIRCH, N.J., COLEMAN, I.P.L., HILBURN, caine in the perfused rat liver M.E. & KARIM, A.R. Factors affecting in situ following flow variations lithium absorption in the rat small in hepatic artery and portal vein, intestine, 158P 403P BIZIERE, K., GUEUDET, C., KAN, J.P., BENNETT, T. & GARDINER, S.M. Antagonism SOUILHAC, J. & WORMS, P. Atypical of the vardiovascular action of vaso- dopaminergic profile of minaprine, a pressin lowers blood pressure in new antidepressant drug, 51P isolated rats, 320P BLACKBURN, T.P., BOWERY, N.G., COX, B., BENNETT, T., GARDINER, S.M. & WINN, HUDSON, A.L., MARTIN, D. & PRICE, G.W. M.J. Factors involved in BP recovery Lesion of the dorsal raphe nucleus following c(- adrenoceptor antagonism: increases the nigral concentration sFudies in Long Evans and Brattleboro of 5-HT1 receptors, 203P rats, 84P BLACKMAN, A. & WOODS, A.M. A mouse - - - The influence of vaso-pressin in vivo model to detect dual on BP following A- adrenoceptor inhibitors of arachidonic acid antagonism, 217P metabolism, 335P BENTLEY, A.M. & OSBORNE, N.N. BLACKHAM, A., NORRIS, A.A. & WOODS, A.M. Feasibility study of a serotonin Modulation of arachidonic acid radioimmunoassay kit assembled from metabolism in immune models of cell commercially available materials, infiltration, 98P 274P BLAIR, I.A. HUGGETT, A. & ORCHARD, M.A. BERN, H.A., BOTTING, J.H., GIBSON,A. & Prostaglandin synthetase catalyzed GINSBURG, M. The effect of some activation of paracetamol by human neuropeptides on tone of the mouse platelets, 67P anococcygeus muscle, 104P BLOWER, P.R. & BOWRING, N.E. The effect BERRIDGE, T.L., DETTMAR, P.W., DOXEY, of acid perfusion and VIP infusion on J.C., GADIE, B., LORD, J.A.H., ROACH, the neutralising capacity of the duo- A.G., TULLOCH, I.F.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Appendix E-3: Complete Search Strategy
    1 Appendix e-3: Complete search strategy The authors initially performed database searches for all studies published in regard to cognitive and emotional disorders in multiple sclerosis. The final guideline focuses solely on emotional disorders. The search strategy presents all results pertaining to emotional disorders unless a search included data on both cognitive and emotional disorders with respect to a particular topic (e.g., interventions). Medline search strategy While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties. Database: Ovid MEDLINE(R) <1950 to February Week 1 2007> Search Strategy: -------------------------------------------------------------------------------- 1 multiple sclerosis/ or multiple sclerosis, chronic progressive/ or multiple sclerosis, relapsing- remitting/ or neuromyelitis optica/ (28475) 2 Demyelinating Diseases/ (7686) 3 clinically isolated syndrome.mp. (67) 4 first demyelinating event.mp. (23) 5 multiple sclerosis.mp. (33263) 6 Demyelinating Disease:.mp. (9613) 7 disseminated sclerosis.mp. (491) 8 or/1-7 (40459) 9 affective symptoms/ (8380) 10 emotions/ or affect/ or irritable mood/ or exp anxiety/ (70058) 11 mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression, postpartum/ or depressive disorder, major/ or dysthymic disorder/ or seasonal affective disorder/ (73853) 12 mood swing:.mp.
    [Show full text]
  • Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy
    UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE FARMACIA Departamento de Farmacología TESIS DOCTORAL Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy Biomarcadores Salivales de Estrés en Pacientes Psicológicos en Tratamiento con Fluoxetina MEMORIA PARA OPTRA AL GRADO DE DOCTOR PRESENTADA POR Nuha Mohammed Yahya Al-Dallee DIRECTORAS María Teresa Ortega Hernández Agero Nahla O.M. Tawfik Madrid, 2017 UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE FARMACIA Departamento de Farmacología Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy Biomarcadores Salivales de Estrés en Pacientes Psicológicos en Tratamiento con Fluoxetina TESIS DOCTORAL Nuha Mohammed Yahya Al-Dallee Madrid, 2017 UNIVERSIDAD COMPLUTENSE DE MADRID FACULITAD DE FARMACIA Departamento de Farmacología Dra. Dña. María Teresa Ortega Hernández-Agero, Profesora Titular, del Departamento de Farmacología de la Facultad de Farmacia de la Universidad de Complutense de Madrid y Dra. Dña. Nahla O. M. Tawfiq, Profesora Titular, de la Facultad de Medicina de la Universidad de Nineveh. CERTIFICAN: Que la presente Tesis Doctoral presentada por Dña. Nuha Mohammed Yahya AL-Dallee, Titulada “Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy”, ha sido realizada bajo nuestra inmediata dirección y asesoramiento. Concluido el trabajo experimental y bibliográfico, autorizamos su presentación para sea juzgada por el Tribunal correspondiente. Madrid, Abril 2017 Dra. María Teresa Ortega Hernández-Agero Dra. Nahla O.M. Tawfiq DEDICATION *TO MY BELOVED COUNTRY IRAQ. *TO THE PEOPLE OF MOSUL CITY, MOSUL WILL RETURN BETTER. *TO MY FATHER & MOTHER. * TO MY LOVELY HUSBEND AND MY GREAT LOVE (BAZIL). TO OUR LIFE AND FUTURE “WASEEM” *TO MY SISTERS & BROTHERS. *TO MY FRIENDS. *TO ALL MEDICAL STUDENTS.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Downloaded for Personal Non-Commercial Research Or Study, Without Prior Permission Or Charge
    https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] 5HT RECEPTORS AND a -ADRENOCEPTORS? CLASSIFICATION, 2 LIGAND BINDING, FUNCTIONAL CORRELATES AND ALTERATIONS IN CEREBRAL ISCHAEMIA. A thesis presented for the degree of Doctor of Philosophy By Christine Mary Brown, BSc Institute of Physiology University of Glasgow & Syntex Research Centre Edinburgh May, 1988. ProQuest Number: 10997942 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10997942 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC.
    [Show full text]
  • Pharmaabkommen A1 E
    Annex I - Pharmaceutical substances, which are free of duty_______________________________________________ Pharmaceutical substances which are Annex I free of duty CAS RN Name 136470-78-5 abacavir 129639-79-8 abafungin 792921-10-9 abagovomab 65195-55-3 abamectin 90402-40-7 abanoquil 183849-43-6 abaperidone 183552-38-7 abarelixe 332348-12-6 abatacept 143653-53-6 abciximab 111841-85-1 abecarnil 167362-48-3 abetimus 154229-19-3 abiraterone 137882-98-5 abitesartan 96566-25-5 ablukast 178535-93-8 abrineurin 91017-58-2 abunidazole 2627-69-2 acadesine 77337-76-9 acamprosate 55485-20-6 acaprazine 56180-94-0 acarbose 514-50-1 acebrochol 26976-72-7 aceburic acid 37517-30-9 acebutolol 32795-44-1 acecainide 77-66-7 acecarbromal 827-61-2 aceclidine 89796-99-6 aceclofenac 77-46-3 acedapsone 127-60-6 acediasulfone sodium 556-08-1 acedoben 80595-73-9 acefluranol 10072-48-7 acefurtiamine 70788-27-1 acefylline clofibrol 18428-63-2 acefylline piperazine 642-83-1 aceglatone 2490-97-3 aceglutamide 110042-95-0 acemannan 53164-05-9 acemetacin 131-48-6 aceneuramic acid 152-72-7 acenocoumarol 807-31-8 aceperone 61-00-7 acepromazine 13461-01-3 aceprometazine 42465-20-3 acequinoline 33665-90-6 acesulfame 118-57-0 acetaminosalol 97-44-9 acetarsol 59-66-5 acetazolamide 3031-48-9 acetergamine 299-89-8 acetiamine 2260-08-4 acetiromate 968-81-0 acetohexamide 546-88-3 acetohydroxamic acid 2751-68-0 acetophenazine 1 / 135 (As of: 1.4.2013) Annex I - Pharmaceutical substances, which are free of duty_______________________________________________ CAS RN Name 25333-77-1 acetorphine
    [Show full text]
  • Customs Tariff - Schedule Xxi - 1
    CUSTOMS TARIFF - SCHEDULE XXI - 1 Section XXI WORKS OF ART, COLLECTORS' PIECES AND ANTIQUES Issued January 1, 2013 CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2013 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT: Free Artificial bait; Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]